Drug Profile
Research programme: autoimmune disease therapy - Lexicon Pharmaceuticals
Alternative Names: LX 2311; LX 2932Latest Information Update: 05 Aug 2019
Price :
$50
*
At a glance
- Originator Lexicon Genetics
- Developer Lexicon Pharmaceuticals
- Class Small molecules
- Mechanism of Action Lyase inhibitors; Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 05 Aug 2019 Preclinical development is ongoing for Autoimmune disorders in USA
- 13 Jan 2014 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
- 11 Dec 2007 Pharmacodynamics data from a preclinical study presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)